trending Market Intelligence /marketintelligence/en/news-insights/trending/5zzr4jfes196bzqcz6sjfw2 content esgSubNav
In This List

Progenics Pharmaceuticals to raise $75M via common stock offering

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Progenics Pharmaceuticals to raise $75M via common stock offering

Progenics Pharmaceuticals Inc. started an underwritten public offering of 9,090,909 common shares, priced $8.25 each.

The New York-based cancer drug developer expects to raise gross proceeds of about $75 million, which will go toward research and development as well as general corporate purposes.

Underwriters have a 30-day option to buy up to 1,363,636 additional common shares on the same terms and conditions.

The offering is expected to close on or around Aug. 10, subject to customary closing conditions.

Jefferies and Credit Suisse are acting as joint book-running managers for the offering, with Cantor Fitzgerald & Co. as lead manager. Needham & Co., BTIG and CIM Securities LLC are acting as co-managers.